
CLAIMS

~~What is claimed is:~~

1. ~~A method of treating a hair loss disorder in a human subject, the method comprising administering to the subject~~Use of a compound represented by the following structural formula:



Compound (I) , or a pharmaceutically acceptable salt thereof;

wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium;

wherein the compound, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hair loss disorder in a human subject, wherein the medicament is suitable for administration ~~is administered~~ for (1) a first period of 8-24 weeks in an amount in the range of about 8 mg to about 32 mg per day, followed by (2) a second period of at least 8 weeks wherein the compound, or pharmaceutically acceptable salt thereof, ~~is administered~~and wherein the medicament is suitable for administration in an amount per day that is 50 to 75 percent of the amount per day ~~administered~~suitable for administration during the first period~~, such that the hair loss disorder is treated~~.

2. The ~~method~~use of claim 1, wherein the hair loss disorder is alopecia areata.

3. The ~~method~~use of any one of claims 1-2, wherein, in the first period, the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration at about 16 mg/day, about 24 mg/day, or about 32 mg per day.

4. The ~~method~~use of any one of claims 1-3, wherein, in the second period, the

compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration at about 8 mg/day, about 12 mg/day, or about 16 mg per day.

5. The ~~method~~use of any one of claims 1-4, wherein in the first period, the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration at about 24 mg/day, and in the second period, the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration at about 16 mg/day.

6. The ~~method~~use of claim 5, wherein the about 24 mg/day of the compound or salt thereof is ~~administered~~suitable for administration once per day, and the about 16 mg/day is ~~administered~~suitable for administration once per day.

7. The ~~method~~use of claim 5, wherein the about 24 mg/day of the compound or salt thereof is ~~administered~~suitable for administration as about 12 mg twice per day, and the about 16 mg/day of the compound or salt thereof is ~~administered~~suitable for administration as about 8 mg twice per day.

8. The ~~method~~use of any one of claims 1-4, wherein in the first period, the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration at about 16 mg/day, and in the second period, the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration at about 8 mg/day.

9. The ~~method~~use of any one of claims 1-8, wherein the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration orally.

10. The ~~method~~use of any one of Claims 1-9, wherein the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration in a pharmaceutical formulation which is a tablet.

11. The ~~method~~use of any one of claims 1-6 or 8-10, wherein the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration once per day in the first period.

12. The ~~method~~use of any one of claims 1-5 or 7-10, wherein the compound, or a pharmaceutically acceptable salt thereof, is ~~administered~~suitable for administration twice per day in the first period.

13. The ~~method~~use of any one of claims 1-12, wherein the first period is about 8-12 weeks.

14. The ~~method~~use of any one of claims 1-12, wherein the first period is about 24 weeks.

15. The ~~method~~use of any one of claims 1-14, wherein the second period is at least 12 weeks.

16. The ~~method~~use of any one of claims 1-15, wherein the second period is at least 24 weeks.

17. The ~~method~~use of any one of claims 1-16, wherein in Compound (I), each position designated specifically as deuterium has at least 97% incorporation of deuterium.

18. The ~~method~~use of any one of claims 1-17, wherein the subject experiences a ≥50% decrease in SALT score at the end of the first period relative to the subject's baseline SALT score prior to ~~treatment~~the use.

19. The ~~method~~use of any one of claims 1-18, wherein the subject's SALT score is less than or equal to 20 at the end of the second period.

20. The ~~method~~use of any one of claims 1-17, wherein the subject's SALT score is less than or equal to 20 at the end of the first period.